ArticlePathology oncology research : POR2009
An immunohistochemical study of colon adenomas and carcinomas: E-cadherin, Syndecan-1, Ets-1.
Article in Pathology oncology research : POR, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Effect of E-cadherin on Prognosis of Colorectal Cancer: A Meta-Analysis Update.Molecular diagnosis & therapy · 2022Pooled it
- Prognostic and clinical significance of syndecan-1 in colorectal cancer: a meta-analysis.BMC gastroenterology · 2015Pooled it
- Downregulated E-cadherin expression indicates worse prognosis in Asian patients with colorectal cancer: evidence from meta-analysis.PloS one · 2013Pooled it
- A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on the APC/β-catenin pathway in the normal mucosa of colorectal adenoma patients.Cancer prevention research (Philadelphia, Pa.) · 2012Trial
- A Novel Immune-Related Prognostic Signature Predicting Survival in Patients with Pancreatic Adenocarcinoma.Journal of oncology · 2022Article
- The auto-inhibition mechanism of transcription factor Ets-1 induced by phosphorylation on the intrinsically disordered region.Computational and structural biotechnology journal · 2022Article
- Syndecan-1 (CD138), Carcinomas and EMT.International journal of molecular sciences · 2021Review
- Syndecan-1 Promotes Hepatocyte-Like Differentiation of Hepatoma Cells Targeting Ets-1 and AP-1.Biomolecules · 2020Article
- Syndecan-1 in Liver Diseases.Pathology oncology research : POR · 2020Article
- Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues.Disease markers · 2019Article
- Syndecan-1-coating of interleukin-17-producing natural killer T cells provides a specific method for their visualization and analysis.World journal of diabetes · 2017Review
- Transcriptional silencing of ETS-1 abrogates epithelial-mesenchymal transition resulting in reduced motility of pancreatic cancer cells.Oncology reports · 2015Article
- Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication.Disease markers · 2015Review
- Prognostic implications of adhesion molecule expression in colorectal cancer.International journal of clinical and experimental pathology · 2015Article
- Integrin αvβ6 and transcriptional factor Ets-1 act as prognostic indicators in colorectal cancer.Cell & bioscience · 2014Article
- The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumors.Frontiers in oncology · 2013Review
- Review of Ets1 structure, function, and roles in immunity.Cellular and molecular life sciences : CMLS · 2013Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is thought that dysregulation of E-cadherin, syndecan-1 (CD138) and Ets-1 is involved in carcinoma development. E-cadherin is an important epithelial cell adhesion molecule; syndecan-1 (CD138) is a regulatory proteoglycan in both cell-cell and cell-matrix adhesion and Ets-1 is a proto-oncogene and transcription factor, which takes part in extracellular matrix remodeling. Our goal was to study the changes in the expression of these molecules during colon carcinoma development and progression. We tested 117 colon adenomas and 149 de novo and ex adenoma carcinomas of the colon, using the Ultravision Polymer system. The positive reaction rate was 100% for E-cadherin, 98.3% for syndecan-1 and 22.4% for Ets-1 in adenomas, while in carcinomas it was 88.5%, 62.4% and 56.3% respectively. We found decreasing expression of E-cadherin and syndecan-1 throughout colon carcinoma progression and an opposite regulation for the Ets-1 protein. Decrease in expression of syndecan-1 is more pronounced in carcinomas compared to E-cadherin. De novo carcinomas have lower E-cadherin and syndecan-1 expression, and higher Ets-1 expression compared to ex adenoma carcinomas. These findings support the hypothesis that there are differences in the carcinogenesis of these tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.